zeleciment rostudirsen

all catalysts(0)

nothing on the calendar yet

News(2)

• 4 potential biotech M&A targets, plus a pretty sure bet from J&J
  Pharma is definitely interested in making more deals. But what biotechs will come under the magnifying glass? BioSpace takes a look at companies that analysts see as near-term targets for buyouts.
  biospace · 16d ago
• Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ review
  If approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…
  biospace · 1mo ago